CL2016002848A1 - Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd - Google Patents

Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd

Info

Publication number
CL2016002848A1
CL2016002848A1 CL2016002848A CL2016002848A CL2016002848A1 CL 2016002848 A1 CL2016002848 A1 CL 2016002848A1 CL 2016002848 A CL2016002848 A CL 2016002848A CL 2016002848 A CL2016002848 A CL 2016002848A CL 2016002848 A1 CL2016002848 A1 CL 2016002848A1
Authority
CL
Chile
Prior art keywords
copd
treatment
formoterol
budesonide
combinations
Prior art date
Application number
CL2016002848A
Other languages
English (en)
Inventor
Michiel Ullmann
Original Assignee
Teva Pharmaceuticals Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51032625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002848(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Europe B V filed Critical Teva Pharmaceuticals Europe B V
Publication of CL2016002848A1 publication Critical patent/CL2016002848A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>ESTA INVENCIÓN PROPORCIONA UN PRODUCTO DE COMBINACIÓN QUE COMPRENDE UNA COMPOSICIÓN INHALABLE DEL ANTAGONISTA MUSCARÍNICO DE ACCIÓN PROLONGADA (LAMA) PARA EL USO EN EL TRATAMIENTO A LARGO PLAZO DE LA COPD EN COMBINACIÓN CON UNA COMPOSICIÓN DE DOSIS FIJA INHALABLE QUE COMPRENDE BUDESONIDA Y FORMOTEROL O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO PARA LA ADMINISTRACIÓN PRO RE NATA (PRN) COMO MEDICACIÓN DE RESCATE PARA EL TRATAMIENTO DE LAS EXACERBACIONES AGUDAS DE LA COPD.</p>
CL2016002848A 2014-05-12 2016-11-09 Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd CL2016002848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1408387.7A GB201408387D0 (en) 2014-05-12 2014-05-12 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
CL2016002848A1 true CL2016002848A1 (es) 2017-07-07

Family

ID=51032625

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002848A CL2016002848A1 (es) 2014-05-12 2016-11-09 Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd

Country Status (17)

Country Link
US (2) US20170209464A1 (es)
EP (2) EP3142653A1 (es)
JP (4) JP2017515835A (es)
KR (2) KR20170003600A (es)
CN (2) CN106488770A (es)
AR (2) AR100369A1 (es)
AU (2) AU2015261103A1 (es)
BR (2) BR112016026371A2 (es)
CA (2) CA2948574A1 (es)
CL (1) CL2016002848A1 (es)
EA (2) EA201692276A1 (es)
GB (1) GB201408387D0 (es)
IL (2) IL248874A0 (es)
MX (2) MX2016014695A (es)
PE (1) PE20170073A1 (es)
UA (2) UA119774C2 (es)
WO (2) WO2015173153A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758294A (zh) * 2014-12-17 2015-07-08 广州呼吸疾病研究所 用于copd、哮喘治疗的吸入药物组合物及其制备方法
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布地奈德和噻托溴铵为活性成分的复方制剂
WO2018071434A1 (en) * 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
CA3091804A1 (en) * 2018-02-23 2019-08-29 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227519B1 (en) * 1991-12-18 2011-07-28 Astra Ab Synergic pharmaceutical composition containing combination of formoterol and budesonide
EP1086697A2 (en) * 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
WO2008021142A2 (en) * 2006-08-09 2008-02-21 Glaxo Group Limited Process for manufacturing lactose
MX2009008794A (es) * 2007-02-19 2009-08-25 Cipla Ltd Combinaciones farmaceuticas al menos de dos broncodilatadores o de un broncodilatador con un corticosteroide.
BRPI0816255A2 (pt) * 2007-09-12 2015-03-17 Glaxo Group Ltd Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
ES2658179T3 (es) * 2010-04-21 2018-03-08 Chiesi Farmaceutici S.P.A. Procedimiento para proporcionar partículas con cargas electrostáticas reducidas
JP2013531056A (ja) * 2010-07-16 2013-08-01 シプラ・リミテッド Ｒ（＋）ブデソニド及び１以上の気管支拡張剤を含む医薬組成物
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RU2460547C1 (ru) * 2011-04-08 2012-09-10 Валерий Феофанович Ушаков Способ пролонгированной профилактики холодового бронхоспазма у больных с "микст-патологией"
US20150165037A1 (en) * 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo

Also Published As

Publication number Publication date
GB201408387D0 (en) 2014-06-25
IL248874A0 (en) 2017-01-31
EA201692276A1 (ru) 2017-03-31
CA2948553A1 (en) 2015-11-19
JP2017515835A (ja) 2017-06-15
WO2015173154A9 (en) 2016-03-03
UA119774C2 (uk) 2019-08-12
PE20170073A1 (es) 2017-03-24
CN106470700A (zh) 2017-03-01
BR112016026369A2 (pt) 2018-05-15
WO2015173154A1 (en) 2015-11-19
AR100369A1 (es) 2016-09-28
CA2948574A1 (en) 2015-11-19
KR20170003601A (ko) 2017-01-09
EP3142653A1 (en) 2017-03-22
KR20170003600A (ko) 2017-01-09
EA201692278A1 (ru) 2017-02-28
MX2016014696A (es) 2017-05-04
JP2020023536A (ja) 2020-02-13
AR100368A1 (es) 2016-09-28
WO2015173153A1 (en) 2015-11-19
MX2016014695A (es) 2017-05-04
JP2017515833A (ja) 2017-06-15
JP2020023537A (ja) 2020-02-13
AU2015261103A1 (en) 2016-11-17
CN106488770A (zh) 2017-03-08
IL248875A0 (en) 2017-01-31
BR112016026371A2 (pt) 2018-06-19
UA119773C2 (uk) 2019-08-12
EP3142654A1 (en) 2017-03-22
AU2015261104A1 (en) 2016-11-17
US20170209464A1 (en) 2017-07-27
US20170202858A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CL2016002848A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CO2017002159A2 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2013002650A1 (es) Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
UY35354A (es) Combinaciones que comprenden compuestos maba y corticosteroides
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
UY35677A (es) Combinaciones que comprenden compuestos maba y corticosteroides
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio